Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2173 in Healthy Participants
NCT07390747Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Mar 2026
- Primary completion
- May 2026
- Modality
- Biological product
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing SHR-2173 single dose with SHR-2173 placebo single dose (2 arms). Primary endpoints: Maximum Observed Plasma Concentration at Day 71, Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration at Day 71 and 4 more. Started Mar 2026; status: completed.
02
Drugs
SHR-2173
Beyond the preview
Go deeper on NCT07390747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07390747.